GlaxoSmithKline Covid-19 Antibody Study Didn't Meet Primary Endpoint
2021年2月25日 - 9:29PM
Dow Jones News
By Cecilia Butini
GlaxoSmithKline PLC said Thursday that a phase-2 trial
evaluating the use of a monoclonal antibody in Covid-19 patients
didn't meet the primary endpoint when tested on patients of all
ages.
The drug, which is named otilimab, failed to achieve significant
improvements in keeping patients free of respiratory failure 28
days after treatment when paired with the existing standard of
care, the British pharmaceutical giant said.
The study, however, did prove that treatment with otilimab was
effective in patients 70 years and older when combined with the
existing standard of care.
As a result, the company said it will amend the study to expand
its investigation in this age group and confirm the findings.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
February 25, 2021 07:14 ET (12:14 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
過去 株価チャート
から 4 2024 まで 5 2024
Gsk (LSE:GSK)
過去 株価チャート
から 5 2023 まで 5 2024
